TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
2.970
+0.040 (1.37%)
At close: Dec 20, 2024, 4:00 PM
3.040
+0.070 (2.36%)
After-hours: Dec 20, 2024, 4:37 PM EST
TScan Therapeutics Employees
TScan Therapeutics had 154 employees as of December 31, 2023. The number of employees increased by 16 or 11.59% compared to the previous year.
Employees
154
Change (1Y)
16
Growth (1Y)
11.59%
Revenue / Employee
$60,792
Profits / Employee
-$722,747
Market Cap
167.82M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 154 | 16 | 11.59% |
Dec 31, 2022 | 138 | 33 | 31.43% |
Dec 31, 2021 | 105 | 47 | 81.03% |
Dec 31, 2020 | 58 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Lyell Immunopharma | 224 |
Caribou Biosciences | 158 |
Nkarta | 150 |
Nektar Therapeutics | 137 |
BrainsWay | 134 |
Kyverna Therapeutics | 96 |
Solid Biosciences | 88 |
Elutia | 54 |
TCRX News
- 12 days ago - TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 16 days ago - TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years - GlobeNewsWire
- 19 days ago - TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy - GlobeNewsWire
- 6 weeks ago - TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition - GlobeNewsWire
- 2 months ago - TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting - GlobeNewsWire
- 4 months ago - TScan Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology - Seeking Alpha
- 4 months ago - TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire